<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005875</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067911</org_study_id>
    <secondary_id>SUPERGEN-RFS2000-10</secondary_id>
    <secondary_id>MDA-DM-98237</secondary_id>
    <nct_id>NCT00005875</nct_id>
  </id_info>
  <brief_title>Nitrocamptothecin in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase II Evaluation of RFS 2000 (9-Nitro-Camptothecin, 9NC) in Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients&#xD;
      who have metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the efficacy and toxicity of nitrocamptothecin in patients with&#xD;
      metastatic melanoma.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease (choroidal vs nonchoroidal). Patients&#xD;
      receive oral nitrocamptothecin daily on days 1-5. Treatment continues weekly for at least 8&#xD;
      weeks (2 courses) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28-74 patients (14-37 per stratum) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rubitecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic melanoma&#xD;
        Choroidal (no prior chemotherapy required) OR Nonchoroidal No more than 3 chemotherapy&#xD;
        regimens Bidimensionally measurable disease No symptomatic uncontrolled CNS involvement&#xD;
        including extensive brain metastases, spinal cord compression, or meningeal carcinomatosis&#xD;
        Not eligible for treatment protocol of higher priority&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Over 16 Performance status: Zubrod 0-2 Life expectancy:&#xD;
        Greater than 8 weeks Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet&#xD;
        count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of&#xD;
        normal (ULN) Transaminase no greater than 3 times ULN Renal: Creatinine no greater than 2.0&#xD;
        mg/dL Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use&#xD;
        effective contraception during and for 1 year after study No serious concurrent illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease&#xD;
        Characteristics At least 3 weeks since prior chemotherapy and recovered Endocrine therapy:&#xD;
        Not specified Radiotherapy: At least 3 weeks since prior radiotherapy and recovered&#xD;
        Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Show-Li Sun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Astex Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SuperGen, Incorporated</name>
      <address>
        <city>Dublin</city>
        <state>California</state>
        <zip>94568</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2001</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>April 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2004</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rubitecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

